Skip to main content

Advertisement

SpringerLink
Log in

Feasibility and effectiveness of inhaled carboplatin in NSCLC patients

  • PHASE II STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Background Inhaled chemotherapy is under investigation as an alternative therapeutic modality for Non-Small Cell Lung Cancer. Methods 60 NSCLC patients were randomized into 3 groups in this study. 20/60 patients (group A—control group) received I.V. chemotherapy (carboplatin AUC ≈ 5.5 D1); 20/60 (group B) received 2/3 of I.V. predicted carboplatin dose by I.V. infusion and the rest 1/3 as aerosol (jet nebulised D1); and 20/60 (group C) received all the predicted I.V. dose of carboplatin as aerosol in 3 equally divided fractions D1-3. In all patients I.V. docetaxel 100/m2 was as well administered (D1). Lung functional tests were performed in all groups before chemotherapy in the 3rd and 6th cycles. Results Group B had a statistically significant increase in survival compared to control group A [275 days (95% CI 249–300) vs. 211 (95% CI 185–236)]. In regard to lung functional tests, a statistically significant decline was observed only in FEV1 of group C in 6 months compared to the initial measurement. Conclusions Inhaled carboplatin could be given as an alternative root of pulmonary drug delivery in selected patients, but further randomized studies remain to prove whether the inhaled chemotherapy is an efficient and safe treatment modality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90. doi:10.3322/caac.20107

    Article  PubMed  Google Scholar 

  2. Brundage MD, Davies D, Mackillop WJ (2002) Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122(3):1037–1057. doi:10.1378/chest.122.3.1037

    Article  PubMed  Google Scholar 

  3. Stewart LA, Pignon JP (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311:899–909

    Article  Google Scholar 

  4. Spiro SG, Rudd RM, Souhami RL, Brown J, Fairlamb DJ, Gower NH, Maslove L, Milroy R, Napp V, Parmar MK, Peake MD, Stephens RJ, Thorpe H, Waller DA, West P, Big Lung Trial Participants (2004) Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 59(10):828–836. doi:10.1136/thx.2003.020164

    Article  CAS  PubMed  Google Scholar 

  5. Albain KS, Crowley JJ, LeBlanc M, Livingston RB (1991) Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9(9):1618–1626

    CAS  PubMed  Google Scholar 

  6. Ando M, Ando Y, Sugiura S, Minami H, Saka H, Sakai S, Shimokata K, Hasegawa Y (1999) Prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer. Jpn J Cancer Res 90(2):249–253

    Article  CAS  PubMed  Google Scholar 

  7. Peng H, Ma M, Han B (2011) Survival analysis of 1,742 patients with stage IV non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 14(4):362–366. doi:10.3779/j.issn.1009-3419.2011.04.11

    PubMed  Google Scholar 

  8. Richter Larsen K, Svendsen UG, Milman N, Brenøe J, Petersen BN (1997) Exercise testing in the preoperative evaluation of patients with bronchogenic carcinoma. Eur Respir J 10(7):1559–1565. doi:10.1183/09031936.97.10071559

    Article  CAS  PubMed  Google Scholar 

  9. Jones LW, Eves ND, Kraus WE, Potti A, Crawford J, Blumenthal JA, Peterson BL, Douglas PS (2010) The lung cancer exercise training study: a randomized trial of aerobic training, resistance training, or both in postsurgical lung cancer patients: rationale and design. BMC Cancer 10:155. doi:10.1186/1471-2407-10-155

    Article  PubMed  Google Scholar 

  10. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non small-cell lung cancer. N Engl J Med 346:92–98

    Article  CAS  PubMed  Google Scholar 

  11. Sharma S, White D, Imondi AR, Placke ME, Vail DM, Kris MG (2001) Development of inhalational agents for oncologic use. J Clin Oncol 19:1839–1847

    CAS  PubMed  Google Scholar 

  12. Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6:583–592. doi:10.1038/nrc1893

    Article  CAS  PubMed  Google Scholar 

  13. Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE 2nd, Zhang C, Mayer RJ (2006) Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24:1395–1403. doi:10.1200/JCO.2005.03.8166

    Article  CAS  PubMed  Google Scholar 

  14. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43

    Article  CAS  PubMed  Google Scholar 

  15. Guerin C, Olivi A, Weingart JD, Lawson HC, Brem H (2004) Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest New Drugs 22:27–37. doi:10.1007/s11060-005-7411-y

    Article  CAS  PubMed  Google Scholar 

  16. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, Maria B, LaFollette S, Schumann GB, Cole BF, Howell SB (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5:3394–3402

    CAS  PubMed  Google Scholar 

  17. Robinson WR, Coberly C, Beyer J, Lewis A, Ballard C (2008) Office-based intraperitoneal chemotherapy for ovarian cancer. J Oncol Pract 4(5):225–228. doi:10.1200/JOP.0858503

    Article  PubMed  Google Scholar 

  18. Hofstra LS, Bos AM, de Vries EG, van der Zee AG, Beijnen JH, Rosing H, Mulder NH, Aalders JG, Willemse PH (2001) A phase I and pharmacokinetic study of intraperitoneal topotecan. Br J Cancer 85(11):1627–1633. doi:10.1054/bjoc.2001.2161

    Article  CAS  PubMed  Google Scholar 

  19. Foote RL, Kasperbauer JL, Okuno SH, Nichols DA, Olsen KD, Brown PD, Garces YI, Sargent DJ, Strome SE (2005) A pilot study of high-dose intra-arterial cisplatin chemotherapy with concomitant accelerated radiotherapy for patients with previously untreated T4 and selected patients with T3N0-3M0 squamous cell carcinoma of the upper aerodigestive tract. Cancer 103(3):559–568. doi:10.1002/cncr.20803

    Article  CAS  PubMed  Google Scholar 

  20. Osaki T, Hanagiri T, Nakanishi R, Yoshino I, Taga S, Yasumoto K (1999) Bronchial arterial infusion is an effective therapeutic modality for centrally located early-stage lung cancer: results of a pilot study. Chest 115:1424–1428. doi:10.1378/chest.115.5.1424

    Article  CAS  PubMed  Google Scholar 

  21. Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl JMed 335(26):1950–1955

    Article  CAS  Google Scholar 

  22. Labiris NR, Dolovich MB (2003) Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 56:588–599. doi:10.1046/j.1365-2125.2003.01892.x

    Article  CAS  PubMed  Google Scholar 

  23. Maisch B, Ristic AD, Pankuweit S, Neubauer A, Moll R (2002) Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin. Eur Heart J 23:1625–1631. doi:10.1053/euhj.2002.3328

    Article  CAS  PubMed  Google Scholar 

  24. Markman M, Cleary S, Pfeifle C, Howell SB (1986) Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma. Cancer 58:18–21. doi:10.1002/1097-0142(19860701)58:1<18::AID-CNCR2820580105>3.0.CO;2-C

    Article  CAS  PubMed  Google Scholar 

  25. Markman M (1996) Intraperitoneal therapy of ovarian cancer. Oncologist 1:18–21

    CAS  PubMed  Google Scholar 

  26. Rusch VW, Figlin R, Godwin D, Piantadosi S (1991) Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial. J Clin Oncol 9:313–319

    CAS  PubMed  Google Scholar 

  27. Okuyama S, Matsumotos K, Saijo H, Suetake M, Yuasa R, Mishina H (1993) Reinforcing aerosol cisplatin for radiotherapy of laryngeal cancer. Tohoku J Exp Med 169(3):253–255

    Article  CAS  PubMed  Google Scholar 

  28. Duvillard C, Romanet P, Cosmidis A, Beaudouin N, Chauffert B (2004) Phase 2 study of intratumoral cisplatin and epinephrine treatment for locally recurrent head and neck tumors. Ann Otol Rhinol Laryngol 113:229–333

    PubMed  Google Scholar 

  29. Goldberg EP, Hadba AR, Almond BA, Marotta JS (2002) Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery. J Pharm Pharmacol 54:159–180. doi:10.1211/0022357021778268

    Article  CAS  PubMed  Google Scholar 

  30. Tatsumura T, Yamamoto K, Murakami A, Tsuda M, Sugiyama S (1983) New chemotherapeutic method for the treatment of tracheal and bronchial cancers G nebulization chemotherapy. Gan No Rinsho 29:765–770

    CAS  PubMed  Google Scholar 

  31. Tatsumura T, Koyama S, Tsujimoto M, Kitagawa M, Kagamimori S (1993) Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical. Br J Cancer 68:1146–1149

    Article  CAS  PubMed  Google Scholar 

  32. Gautam A, Koshkina N (2003) Paclitaxel (Taxol) and taxoid derivates for lung cancer treatment: potential for aerosol delivery. Curr Cancer Drug Targets 3:287–296

    Article  CAS  PubMed  Google Scholar 

  33. Hershey AE, Kurzman ID, Forrest LJ, Bohling CA, Stonerook M, Placke ME, Imondi AR, Vail DM (1999) Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin Cancer Res 5(9):2653–2659

    CAS  PubMed  Google Scholar 

  34. Koshkina NV, Golunski E, Roberts LE, Gilbert BE, Knight V (2004) Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. J Aerosol Med 17(1):7–14. doi:10.1089/089426804322994415

    Article  CAS  PubMed  Google Scholar 

  35. Minchin RF, Johnston MR, Aiken MA, Boyd MR (1984) Pharmacokinetics of doxorubicin in isolated lung of dogs and humans perfused in vivo. J Pharmacol Experim Therap 229(1):193–198

    CAS  Google Scholar 

  36. Otterson GA, Villalona-Calero MA, Hicks W, Pan X, Ellerton JA, Gettinger SN, Murren JR (2010) Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer. Clin Cancer Res 16(8):2466–2473. doi:10.1158/1078-0432.CCR-09-3015

    Article  CAS  PubMed  Google Scholar 

  37. Wittgen BPH, Kunst PWA, van der Born K, van Wijk AW, Perkins W, Pilkiewicz FG, Perez-Soler R, Nicholson S, Peters GJ, Postmus PE (2007) Phase I Study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res 13(8):2414–2421. doi:10.1158/1078-0432.CCR-06-1480

    Article  CAS  PubMed  Google Scholar 

  38. Selting K, Waldrep JC, Reinero C, Branson K, Gustafson D, Kim DY, Henry C, Owen N, Madsen R, Dhand R (2008) Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe® intracorporeal nebulization catheter. J Aerosol Med Pulm Drug Deliv 21(3):255–268. doi:10.1089/jamp.2008.0684

    Article  CAS  PubMed  Google Scholar 

  39. Khanna C, Vail DM (2003) Targeting the lung: preclinical and comparative evaluation of anticancer aerosols in dogs with naturally occurring cancers. Curr Cancer Drug Targets 3(4):265–273

    Article  CAS  PubMed  Google Scholar 

  40. Kleinstreuer C, Zhang Z, Donohue JF (2008) Targeted drug-aerosol delivery in the human respiratory system. Annu Rev Biomed Eng 10:195–220. doi:10.1146/annurev.bioeng.10.061807.160544

    Article  CAS  PubMed  Google Scholar 

  41. Laube BL (2005) The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 50:1161–1176

    PubMed  Google Scholar 

  42. Zarogoulidis P, Papanas N, Kouliatsis G, Spyratos D, Zarogoulidis K, Maltezos E (2011) Inhaled insulin: too soon to be forgotten? J Aerosol Med Pulm Drug Deliv. doi:10.1089/jamp.2011.0876 [Epub ahead of print]

  43. Shevchenko IT, Resnik GE (1968) Inhalation of chemical substances and oxygen in radiotherapy of bronchial cancer. Neoplasma 15:419–426

    CAS  PubMed  Google Scholar 

  44. Camus P, Fanton A, Bonniaud P, Camus C, Foucher P (2004) Interstitial lung disease induced by drugs and radiation. Respiration 71:301–326. doi:10.1159/000079633

    Article  PubMed  Google Scholar 

  45. Camus P (2004) Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management. Br J Cancer 91(Suppl 2):S1–S2. doi:10.1038/sj.bjc.6602060

    Article  PubMed  Google Scholar 

  46. Sarna L, Padilla G, Holmes C, Tashkin D, Brecht ML, Evangelista L (2002) Quality of life of long-term survivors of non-small-cell lung cancer. J Clin Oncol 20:2920–2929. doi:10.1200/JCO.2002.09.045

    Article  PubMed  Google Scholar 

  47. Moore MJ, Erlichman C (1998) Pharmacology of anticancer drugs. In: Tannock IF, Hill RP (eds) The basic science of oncology, 3rd edn. McGraw-Hill Health Professions Division, New York, pp 370–391

    Google Scholar 

  48. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J (2005) ATS/ERS Task Force: standardisation of spirometry. Eur Respir J 26(2):319–338. doi:10.1183/09031936.00130010

    Article  CAS  PubMed  Google Scholar 

  49. ICH HARMONISED TRIPARTITE GUIDELINE (1995) Published in the Federal Register, Vol. 60, No. 40, p. 11264–11268, 1 http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S3A/Step4/S3A_Guideline.pdf

  50. WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI. Ethical Principles for Medical Research Involving Human Subjects http://www.wma.net/en/30publications/10policies/b3/17c.pdf

  51. Krilov LR (2002) Safety issues related to the administration of ribavirin. Pediatr Infect Dis J 21:479–481

    Article  PubMed  Google Scholar 

  52. Ros JJ, Langen MC, Stallen PC, Lenderink AW (1996) Pentamidine aerosols and environmental contamination: health-care workers at risk. Pharm World Sci 18:148–152

    Article  CAS  PubMed  Google Scholar 

  53. Wahlin B, Malmstrom B, Soop M, Hellstrom LG (1996) A paediatric canopy system for aerosol administration and minimized environmental pollution. Acta Anaesthesiol Scand 40:932–939

    Article  CAS  PubMed  Google Scholar 

  54. Chou AJ, Bell MD, Mackinson C, Gupta R, Meyers PA, Gorlick R (2007) Phase Ib/IIa study of sustained release lipid inhalation targeting cisplatin by inhalation in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. J Clinical Oncology. ASCO Annual Meeting Proceedings Part I, 25(18Suppl):9525

    Google Scholar 

  55. Geller DS, Gorlick R (2010) Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 8(10):705–718

    PubMed  Google Scholar 

  56. Morrow PE. Conference on the scientific basis of respiratory therapy. Aerosol therapy. Aerosol characterization and deposition. Am Rev Respir Dis 110:88–99

  57. ICH HARMONISED TRIPARTITE GUIDELINE SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS S7A (2000) http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf

  58. Gagnadoux F, Hureaux J, Vecellio L, Urban T, Le Pape A, Valo I, Montharu J, Leblond V, Boisdron-Celle M, Lerondel S, Majoral C, Diot P, Racineux JL, Lemarie E (2008) Aerosolized chemotherapy. J Aerosol Med Pulm Drug Delivery 21(1):61–70. doi:10.1089/jamp.2007.0656

    Article  CAS  Google Scholar 

  59. Lipworth BJ (1996) Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol 42(6):697–705. doi:10.1046/j.1365-2125.1996.00493.x

    Article  CAS  PubMed  Google Scholar 

  60. Laube BL (2005) The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 50(9):1161–1176

    PubMed  Google Scholar 

  61. Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0.June 1, 1999. http://ncictephelp@ctep.nci.nih.gov

  62. Gavini E, Manunta L, Giua S, Achenza G, Giunchedi P (2005) Spray-dried poly(D,L-lactide) microspheres containing carboplatin for veterinary use: in vitro and in vivo studies. AAPS PharmSciTech 20;6(1):E108-E114. doi: 10.1208/pt060117

    Google Scholar 

  63. Morrison JG, White P, McDougall S, Firth JW, Woolfrey SG, Graham MA, Greenslade D (2000) Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin. J Pharmaceut Biomed Anal (24):1–10. doi:10.1016/S0731-7085(00)00377-0

  64. Tibben MM, Rademaker-Lakhai JM, Rice JR, Stewart DR, Schellens JHM, Beijnen JH (2002) Determination of total platinum in plasma and plasma ultrafiltrate, from subjects dosed with the platinum-containing N-(2-hydroxypropyl)methacrylamide copolymer AP5280, by use of graphite-furnace Zeeman atomic-absorption spectrometry. Anal Bioanal Chem 373:233–236. doi:10.1007/s00216-002-1340-9

    Article  CAS  PubMed  Google Scholar 

  65. Villarino N, Cox S, Yarbrough J, Martín-Jiménez T (2010) Determination of carboplatin in canine plasma by high-performance liquid chromatography. Biomed Chromatogr 24(8):908–913. doi:10.1002/bmc.1385

    CAS  PubMed  Google Scholar 

  66. Trotti A, Byhardt R, Stetz J, Corn B, Fu K, Gunderson L, McCormick B, Morris M, Tyvin Rich, Shipley W, Curran W (2000) Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol* Biol* Phys (IJROBP) 47(1):13–47. doi:10.1016/S0360-3016(99)00559-3

    Article  CAS  Google Scholar 

  67. Eisenhauer EA, Therasse P, Bogaerts J, Schwart LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. doi:10.1016/j.ejca.2008.10.026

    Article  CAS  PubMed  Google Scholar 

  68. Wang Z, Chen HT, Roa W, Finlay W (2003) Farnesol for aerosol inhalation: nebulization and activity against human lung cancer cells. J Pharm Pharm Sci 6:95–100

    PubMed  Google Scholar 

  69. Yancik R (1997) Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 80(7):1273–1283. doi:10.1002/(SICI)1097-0142(19971001)80:7<1273::AID-CNCR13>3.0.CO;2-4

    Article  CAS  PubMed  Google Scholar 

  70. Piepoli MF, Davos C, Francis DP, Coats AJ, ExTraMATCH Collaborative (2004) Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 328(7433):189. doi:10.1136/bmj.37938.645220.EE

    Article  CAS  PubMed  Google Scholar 

  71. International Commission on Radiological Protection (1994) Human respiratory tract model for radiological protection. Elsevier Science Ltd; ICRP Publication 66; Ann. ICRP 24(1/3), Oxford

  72. Clay MM, Pavia D, Newman SP, Clarke SW (1983) Factors influencing the size distribution of aerosols from jet nebulisers. Thorax 38(10):755–759

    Article  CAS  PubMed  Google Scholar 

  73. Khalid MN, Simard P, Hoarau D, Dragomir A, Leroux JC (2006) Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors. Pharm Res 23(4):752–758. doi:10.1007/s11095-006-9662-5

    Article  CAS  PubMed  Google Scholar 

  74. Hitzman CJ, Wattenberg LW, Wiedmann TS (2006) Pharmacokinetics of 5-Fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles. J Pharm Sci 95:1196–1211. doi:10.1002/jps.20607

    Article  CAS  PubMed  Google Scholar 

  75. Hureaux J, Lagarce F, Gagnadoux F, Vecellio L, Clavreul A, Roger E, Kempf M, Racineux JL, Diot P, Benoit JP, Urban T (2009) Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel. Eur J Pharmac Biopharmac 73(2):239–246. doi:10.1016/j.ejpb.2009.06.013

    Article  CAS  Google Scholar 

  76. Koshkina NV, Waldrep JC, Roberts LE, Golunski E, Melton S, Knight V (2001) Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 7(10):3258–3262

    CAS  PubMed  Google Scholar 

  77. Ajay G, Nadezhda K (2003) Paclitaxel (Taxol) and taxoid derivates for lung cancer treatment: potential for aerosol delivery. Curr Cancer Drug Targets 3:287–296

    Article  Google Scholar 

  78. Utsuki T, Brem H, Pitha J, Loftsson T, Kristmundsdottir T, Tyler BM, Olivi A (1996) Potentiation of anticancer effects of microencapsulated carboplatin by hydroxypropyl α-cyclodextrin. J Contr Release 40(3):251–260. doi:10.1016/0168-3659(95)00192-1

    Article  CAS  Google Scholar 

  79. Chen W, Lu DR (1999) Carboplatin-loaded PLGA microspheres for intracerebral injection: formulation and characterization. J Microencapsul 16(5):551–563. doi:10.1080/026520499288753

    Article  CAS  PubMed  Google Scholar 

  80. Stegen K, Neujens A, Crombez G, Hermans D, Van de Woestijne KP, Van den Bergh O (1998) Negative effect, respiratory reactivity, and somatic complaints in a CO2 enriched air inhalation paradigm. Biol Psychol 49(1–2):109–122

    Article  CAS  PubMed  Google Scholar 

  81. Koshkina NV, Knight V, Gilbert BE, Golunski E, Roberts L, Waldrep JC (2001) Improved respiratory delivery of the anticancer drugs, camptothecin and Paclitaxel, with 5% CO2-enriched air: pharmacokinetic studies. Cancer Chemother Pharmacol 47(5):451–456

    Article  CAS  PubMed  Google Scholar 

  82. Newsom Davis J, Stagg D (1975) Interrelationships of the volume and time components of individual breaths in resting man. J Physiol 245:481–498

    Google Scholar 

  83. Usmani OS, Barnes PJ (2011) The small airways: an important target in asthma and COPD treatment. Respir Dis Pract 21:1–4. doi:10.3109/07853890.2011.585656

    Google Scholar 

Download references

Competing interests

The authors declare that they have no competing interests.

Author information

Authors and Affiliations

  1. Aristotle University Pulmonary Department, “G. Papanikolaou” Hospital, Thessaloniki, Greece

    Paul Zarogoulidis, Ellada Eleftheriadou, Iordanis Sapardanis, Vasiliki Zarogoulidou, Helliel Lithoxopoulou, Maria Mabroudi & Kostantinos Zarogoulidis

  2. Bronchoscopic Unit, “G. Papanikolaou” Hospital, Thessaloniki, Greece

    Theodoros Kontakiotis

  3. Laboratory of Biochemistry, University of Patras, Patras, Greece

    Nikolaos Karamanos

  4. Laboratory of Analytical Chemistry, Department of Chemistry, Aristotle University of Thessaloniki, Thessaloniki, Greece

    George Zachariadis

  5. Nuclear Medicine Department, Democritus University of Thrace, Alexandroupolis, Greece

    Athanasios Zisimopoulos

Authors
  1. Paul Zarogoulidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ellada Eleftheriadou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Iordanis Sapardanis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vasiliki Zarogoulidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Helliel Lithoxopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Theodoros Kontakiotis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nikolaos Karamanos
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. George Zachariadis
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Maria Mabroudi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Athanasios Zisimopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kostantinos Zarogoulidis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul Zarogoulidis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zarogoulidis, P., Eleftheriadou, E., Sapardanis, I. et al. Feasibility and effectiveness of inhaled carboplatin in NSCLC patients. Invest New Drugs 30, 1628–1640 (2012). https://doi.org/10.1007/s10637-011-9714-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-011-9714-5

Keywords

Search

Navigation